TCA drug test: What it detects, cutoffs, and false positives

A TCA drug test is a urine or blood screening panel that detects tricyclic antidepressants (TCAs) and their metabolites.

Practices order it in emergency toxicology, in medication compliance monitoring, and inside extended workplace panels.

According to MedlinePlus (National Library of Medicine), TCA screens are most often ordered when overdose is suspected. The other common reason is verifying that a patient is taking a prescribed medication. The screen returns a positive or negative result against a standard immunoassay cutoff of 300 ng/mL.

A positive screen is preliminary, and confirmatory testing has to follow before any clinical or legal action does. This guide covers which drugs the panel detects, how cutoff levels work, and what causes false positives. It also shows how to document a result so it holds up later.

Found our content helpful?

Key takeaways

TCA stands for tricyclic antidepressant, a medication class used for depression, anxiety, and chronic pain. The panel detects these compounds in urine or blood.

The standard immunoassay screening cutoff is 300 ng/mL, and a result at or above it triggers confirmatory GC-MS or LC-MS/MS testing.

Several non-TCA medications, including carbamazepine, quetiapine, cyclobenzaprine, and diphenhydramine, can cause false positive results on immunoassay screens.

Detection windows run roughly 2 to 7 days after therapeutic use, and up to about 10 days with chronic high-dose use.

Pabau’s lab order tracking helps practices record the screening order, file the confirmatory result, and flag positives for clinician review.

What is TCA on a drug test?

TCA stands for tricyclic antidepressant, a class of medications that act on serotonin and norepinephrine reuptake pathways in the brain. On a drug test, a TCA panel is a urine or blood immunoassay that detects these compounds above a defined concentration threshold. The screen does not separate legitimate prescription use from misuse, which is why every positive result needs confirmation.

TCAs were developed in the 1950s and 1960s and remain in clinical use today. Psychiatrists, primary care physicians, and pain specialists prescribe them for depression, anxiety disorders, neuropathic pain, migraines, and insomnia. A screen becomes clinically relevant when a patient’s prescription history meets a multi-panel workplace or probationary drug test.

Standard 5-panel DOT tests do not include TCAs, but 10-panel and 12-panel screens often do. Practices that manage patients on long-term antidepressants need one clear process for recording the test order and the result interpretation. That process belongs in the same system as the patient record, which is what therapy practice management software is built to hold.

Which drugs does a TCA test detect?

A TCA panel screens for the tricyclic antidepressants below, along with their active metabolites. The Quest Diagnostics TCA quantitative urine panel (test #39411) lists seven compounds as the standard analytes for therapeutic monitoring.

The panel also detects active metabolites. Amitriptyline breaks down into nortriptyline, so both the parent compound and the metabolite show up in urine after amitriptyline use. That cross-detection helps verify compliance, but it complicates interpretation when a patient is prescribed nortriptyline on its own.

Record the patient’s full medication list before you read a TCA result. A structured psychiatric evaluation template keeps that list beside the rest of the assessment, so the person interpreting the screen is not working from memory.

TCA drug test cutoff levels explained

The standard immunoassay screening cutoff is 300 ng/mL. A urine sample at or above that level returns a positive preliminary result. Below it, the test reports negative even when trace amounts are present. That 300 ng/mL threshold comes from commercial reference laboratory standards rather than a federal mandate, and the major reference labs apply it consistently.

Screening cutoffs are not the same as confirmation cutoffs. When a sample clears 300 ng/mL on immunoassay, the lab sends it for GC-MS or LC-MS/MS confirmation. Confirmation labs work to cutoffs set per compound rather than one universal threshold. Desipramine and nortriptyline have different pharmacokinetic profiles from amitriptyline, and those differences shape the compound-specific limits.

Quantitative TCA monitoring is a different ordering context from immunoassay screening. A practice ordering a quantitative test wants more than a presence or absence answer. It needs to know whether the serum or urine concentration sits inside the therapeutic range for the prescribed dose. This is standard work in therapeutic drug monitoring (TDM) programs.

When and why is TCA testing used?

TCA screening turns up across several clinical and occupational settings. The reason for ordering decides which test fits: a qualitative immunoassay for presence or absence, or quantitative monitoring for therapeutic optimization.

• Emergency toxicology: TCAs are among the most dangerous medications in overdose, and a single-tablet overdose in a child can be fatal. Emergency physicians order TCA screens as soon as overdose is suspected, because the QRS widening and arrhythmias of TCA toxicity need rapid identification.
• Medication compliance monitoring: Psychiatrists and pain management physicians use TCA screens to confirm that a patient is taking a prescribed medication. A negative screen in a patient supposedly on amitriptyline warrants a clinical conversation.
• Workplace and probationary drug testing: Extended panels ordered by employers, probation officers, or substance abuse treatment programs may include TCA. The rationale is detecting psychoactive substance use, though legitimate prescription holders are protected from adverse action once confirmatory testing is done.
• Substance abuse treatment monitoring: Rehabilitation and outpatient addiction programs use TCA panels to monitor polydrug use patterns in patients with complex histories.

Clinicians ordering a TCA screen should record the clinical indication clearly. An emergency screen, a compliance check, and a workplace panel carry different chain-of-custody and reporting requirements. Mixing up the documentation for those use cases creates clinical and legal exposure for the practice. A mental health EMR that stores the indication alongside the order keeps the three apart.

What causes a false positive TCA drug test?

False positives on TCA immunoassay screens happen because the antibody reagents cross-react with structurally similar molecules. This is the most clinically significant limitation of the immunoassay method, and it is well documented in peer-reviewed literature. The AnnClinLabSci validation study reported quetiapine, cyclobenzaprine, and antihistamines among the interfering substances it tested.

Substances documented to cause false positive TCA results include:

• Carbamazepine (Tegretol): An anticonvulsant and mood stabilizer with a tricyclic-like ring structure. Cross-reactivity is documented in published validation work and in clinical case reports. Patients on carbamazepine for epilepsy or bipolar disorder frequently trigger positive TCA screens.
• Quetiapine (Seroquel): An atypical antipsychotic whose metabolic byproducts cross-react with TCA immunoassay reagents. Quetiapine is widely prescribed for bipolar disorder, schizophrenia, and off-label insomnia, so it is a common source of unexpected positives in psychiatric populations.
• Diphenhydramine (Benadryl): The active ingredient in many over-the-counter antihistamines and sleep aids. It is structurally distinct from TCAs, but it is documented to trigger cross-reactivity at higher doses.
• Cyclobenzaprine (Flexeril): A muscle relaxant whose chemical structure closely resembles amitriptyline. That structural similarity makes it one of the highest-risk false-positive triggers on the panel.

Confirmatory GC-MS or LC-MS/MS testing settles a false positive. Mass spectrometry identifies the specific molecular structure in the sample, which separates a TCA from a cross-reactive substance. No clinical or employment decision should rest on an unconfirmed immunoassay positive.

What does a positive TCA result mean?

A positive screen means the urine sample contains one or more compounds that reacted with the immunoassay antibody above the 300 ng/mL threshold. It does not name the compound, and it does not establish misuse. The University of Rochester Medical Center notes that results are reported as positive or negative against cutoff thresholds, with confirmation required before clinical action.

Three scenarios produce a positive immunoassay screen:

1. Legitimate prescription use: A patient taking amitriptyline, nortriptyline, or another TCA at a therapeutic dose will test positive. This is expected, not a concern. Confirmatory testing names the specific drug, and the prescription history explains the finding.
2. Cross-reactive substance: A patient on carbamazepine, quetiapine, or cyclobenzaprine may test positive with no TCA in their system. Confirmation resolves this by identifying what is present.
3. Non-prescribed TCA use: A patient using a TCA without a current prescription. Confirmation names the specific compound, and the clinical response depends on context.

Confirmation is what separates those three, and the route from a positive screen to a result you can act on looks the same each time.

Treat every positive immunoassay as preliminary. Document it, order confirmation, and read the confirmed result against the patient’s current medication list before you draw conclusions.

How long does TCA stay in your system?

TCA detection windows in urine usually run 2 to 7 days after standard therapeutic use, though individual factors move that considerably. Chronic use at higher doses can stretch detection to roughly 10 days. These are general ranges drawn from multiple laboratory sources. No single window applies to everyone, because tricyclic antidepressants have long and variable elimination half-lives.

Do not read a published range as a precise pharmacokinetic guarantee. A patient who stopped amitriptyline five days ago may still test positive, or may already be negative, depending on their clearance profile. When the timing of the last dose matters clinically, a quantitative TCA test tells you more than a qualitative screen.

How to document TCA screening in practice

Ordering the test is the small part of the workflow. What holds up later is the record around it. That record needs the indication for testing, the result received, the confirmatory outcome, and the clinical decision that followed. Outpatient psychiatry and pain management run TCA screens routinely, and the record often stops at the result.

A documented chain from indication to order to screening result to confirmatory result to clinical response is the standard a well-run practice should meet. It matters most when a positive screen has to be explained to an employer, an insurer, or a regulator.

Three points in the workflow are where the record most often stops short:

1. Recording the clinical indication at the time of ordering. “Drug screen ordered” is not enough. The record should say whether the screen was for compliance monitoring, overdose assessment, or inclusion in a multi-substance panel.
2. Linking the screening result to confirmatory follow-up. A positive immunoassay that is never confirmed leaves an unresolved record, which causes problems in employment and legal contexts. The practice needs a protocol that triggers confirmatory ordering whenever a screen comes back positive.
3. Documenting the prescription context. If a patient is prescribed amitriptyline and tests positive, that prescription record should sit alongside the test result in the patient file. Access to the file should be logged too, because screening results are among the most sensitive data a practice holds.

Lab order tracking inside a practice management platform holds that chain in one place. Results return to the patient record and get flagged for clinician review, so the follow-up step does not depend on someone remembering to chase it.

Patient communication belongs in the workflow too. A patient taking a prescribed TCA who faces employment drug testing should know in advance that the immunoassay stage may read positive. Tell them that this is not a failure, and that confirmation testing will identify their medication accurately. Saying it up front reduces distress and makes patients less likely to avoid testing altogether.

How Pabau keeps TCA screening documented end to end

Most practices run TCA screening across three disconnected systems. The order goes out through a lab portal, and the result arrives back by fax or email. The clinician’s interpretation is then typed into a note that links to neither. Reconstructing that chain months later takes an afternoon.

Practice management software like Pabau keeps the order, the result, and the interpretation on one patient record. The indication is captured as a structured field when the order is raised, so the reason for testing is recorded before anyone knows the outcome. Returned results are flagged for clinician review instead of sitting in a shared inbox.

Psychiatry EMR software earns its place in a high-volume medication practice for the same reason. When medication lists, screening orders, and confirmatory results sit together, reading a positive screen against a current prescription takes seconds rather than a phone call. Every Pabau subscription includes the full feature set, so none of this sits behind a higher tier.

Keep lab documentation and compliance tracking in one place

Pabau helps psychiatric and primary care practices record TCA screening orders, track results, and flag positive screens for clinician review, all inside a HIPAA-compliant workflow. No disconnected paper trails.

Book a demo

Conclusion

The value of a TCA screen depends on what the practice does after it. On its own, the screen reports that something reacted with an antibody above 300 ng/mL. Confirmation turns that into a clinical fact, and the patient’s medication list turns the fact into a decision.

So build the confirmation step into the protocol rather than leaving it to whoever happens to read the result. Tell patients on prescribed TCAs what to expect before an employer tests them. Both steps cost a few minutes and head off the situations that take weeks to unwind.

Pabau keeps the indication, the screening result, and the confirmatory result on one patient record. Book a demo to see how that works in a psychiatry or pain management practice.

Continue your research

Choosing a system for a psychiatry practice? Psychiatry EHR walks through what medication-heavy practices should look for before they commit.

Need a structured framework for mental health assessments? Psychiatric evaluation template gives you a step-by-step structure that captures the full medication list.

Tracking how a patient responds to a prescription? ADHD medication side effects monitoring sheet shows how a simple monitoring record is laid out.

Assessing a patient with a substance use history? Drug and alcohol evaluation covers the questions a screening result rarely answers on its own.

Frequently asked questions